Logo-jnp
Editorial

1. Mycophenolate mofetil for the treatment of Henoch-Schönlein purpura nephritis; current knowledge and new concepts
Azar Nickavar*, Mahnaz Sadeghian
J Nephropathol. 2017;6(3): 103-104. doi: 10.15171/jnp.2017.17
PMCID: PMC5607967     PMID: 28975086     Scopus ID: 85019874039    
Article
PDF
XML
Cited By:
3
1
1
Original Article

2. Risk factors for cytomegalovirus disease in seropositive renal transplant recipients; a single-center case-controlled study
Viviana Navarro-Rodríguez, Alvaro Herrera-Munoz, Adrián Castro, Allan Ramos-Esquivel*
J Nephropathol. 2017;6(3): 240-247. doi: 10.15171/jnp.2017.39
PMCID: PMC5607989     PMID: 28975107     Scopus ID: 85019967364    
Article
PDF
XML
Cited By:
5
0
6
Original Article

3. Mycophenolate mofetil versus cyclophosphamide for idiopathic membranous nephropathy; a double blind and randomized clinical trial
Fatemeh Hayati, Heshmatollah Shahbazian, Ali Ghorbani, Shahla Ahmadi Halili*, Eisa Rezaei, Leila Sabetnia, Seyed Seifollah Beladi Mousavi
J Nephropathol. 2019;8(2): e12. doi: 10.15171/jnp.2019.12
Scopus ID: 85065879302    
Article
PDF
XML
Cited By:
1
1
Case Report

4. Light chain deposition disease as monoclonal gammopathy of renal significance-a rare disease with scarce therapy; a case report
Fereshteh Saddadi ORCID, Bahareh Marghoob* ORCID, Mohamadhasan Fallahkohan ORCID
J Nephropathol. 2024;13(4): e25550. doi: 10.34172/jnp.2024.25550
Scopus ID: 85202569622    
Article
PDF
XML
Cited By:
0